Asciminib

1 Drug classified under this active ingredient

Tyrosine Kinase Inhibitor. Asciminib 20 mg, 40 mg.
FC Tabs.20/60 X 20 mg/40 mg
Ph+ CML in chronic phase: 80 X 1/d
Ph+ CML in CP with the T315I mutation: 200 X2/d
Tmt of adults with: 1. Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), prev. treated with two or more tyrosine kinase inhibitors (TKIs.) 2.  Ph+ CML in CP with the T315I mutation.
C/I: Hypersens.